Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KTTA

KTTA - Pasithea Therapeutics Corp. Stock Price, Fair Value and News

$0.86+0.01 (+1.18%)
Market Closed

79/100

KTTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

79/100

KTTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.35

Target 3M

$1.05

Target 6M

$1.22

KTTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KTTA Price Action

Last 7 days

-5.5%

Last 30 days

-24.6%

Last 90 days

2.4%

Trailing 12 Months

-65.9%

KTTA RSI Chart

KTTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KTTA Valuation

Market Cap

6.4M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

20.4

EV/EBITDA

-0.34

Price/Free Cashflow

-0.52

KTTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.35

Target 3M

$1.05

Target 6M

$1.22

KTTA Fundamentals

KTTA Revenue

Revenue (TTM)

423.2K

Rev. Growth (Yr)

-42.2%

Rev. Growth (Qtr)

-17.6%

KTTA Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-1.25%

Earnings Growth (Qtr)

18.26%

KTTA Profitability

EBT Margin

-3188.80%

Return on Equity

-110.55%

Return on Assets

-99%

Free Cashflow Yield

-191.48%

KTTA Investor Care

Shares Dilution (1Y)

487.76%

Diluted EPS (TTM)

-5.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024698.5K572.2K515.5K423.2K
202300604.6K763.9K
2022000486.6K
20210000
Get all data in R, Python etc through our Historical Stock Data APIs

About Pasithea Therapeutics Corp.

KTTA
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
 CEO
 WEBSITEpasithea.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Pasithea Therapeutics Corp. Frequently Asked Questions

KTTA is the stock ticker symbol of Pasithea Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Pasithea Therapeutics Corp. is 6.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KTTA's fair value in chart for subscribers.

The fair value guage provides a quick view whether KTTA is over valued or under valued. Whether Pasithea Therapeutics Corp. is cheap or expensive depends on the assumptions which impact Pasithea Therapeutics Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KTTA.

As of Wed Jan 28 2026, KTTA's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 20.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTTA PE ratio will change depending on the future growth rate expectations of investors.